Alfred Merz appointed as CEO of ProBioGen

Ella Day | March 31, 2025 | Appointment | Manufacturing Services, Manufacturing and Production CEO, Pharmacy, ProBioGen, appointment, biotech 

ProBioGen has announced the appointment of Alfred Merz as its chief executive officer (CEO), effective 1 April 2025. Merz, who was previously chief operating officer (COO) and interim CEO, now assumes leadership of the company.

Merz has over 30 years’ worth of experience in manufacturing, operations and strategy development. Before joining ProBioGen 2024, he was senior vice president and head of product supply medical devices at Bayer Pharmaceuticals. He also has experience at Novartis.

ProBioGen is a biotech company, a contract development and manufacturing organisation (CDMO) and technology provider that operates globally. It specialises in developing and manufacturing active pharmaceutical ingredients, viral vectors and vaccines. It also develops and outlicenses proprietary technologies that improve product quality and features.

Advertisement

Merz stated: “ProBioGen has a strong legacy of innovation and excellence in CDMO services and technologies. I am honoured to lead this outstanding team as we accelerate our growth, expand our capabilities, and continue delivering high-quality solutions for our pharma and biotech partners.”

Additionally, Wafik Bardissi, chairman of ProBioGen’s supervisory board and CEO of Minapharm Pharmaceuticals, commented on the appointment: “Alfred embodies impressive leadership and business acumen. His strategic expertise is vital to accelerating ProBioGen’s growth…”

Ella Day
31/3/25

Related Content

Lilly opens fourth US Gateway Labs site

Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …

drug-trials

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

Lilly secures conditional MHRA approval for new blood cancer treatment

Crown Bioscience opens new US model development centre

Crown Bioscience, a US global contract research organisation (CRO) that is part of JSR Life …

The Gateway to Local Adoption Series

Latest content